Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Host NLRP6 exacerbates graft-versus-host disease independent of microbial diversity

PROVIDER: PRJNA491725 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7873480_1.fastq.gz	Fastqsanger.gz
	SRR7873480_2.fastq.gz	Fastqsanger.gz
	SRR7873490_1.fastq.gz	Fastqsanger.gz
	SRR7873490_2.fastq.gz	Fastqsanger.gz
	SRR7873500_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 120

Similar Datasets

Host NLRP6 exacerbates graft-versus-host disease independent of microbial diversity

Project description:Host NLRP6 regulates innate immune responses and gastrointestinal (GI) homeostasis. It plays a protective role in pathogenic processes such as intestinal colitis and tumorigenesis in a microbiome dependent manner. Host innate immunity and changes in microbial diversity also play a role in the severity of allo-immune-mediated gastrointestinal pathogenic process, namely graft-versus-host disease (GVHD), the principal toxicity after allogeneic bone marrow transplantation (allo-BMT). Herein, we examined the role of NLRP6 in multiple murine models of allo-BMT. In contrast to its role in intestinal colitis, host NLRP6 aggravated GI GVHD. NLRP6-deficient animals showed improved intestinal barrier function, increased levels of tissue repair associated proteins and preserved Goblet and Paneth cell numbers in the GI tract after allo-BMT. The impact of host NLRP6 deficiency in mitigating GVHD was observed regardless of co-housing, antibiotic treatment, or colonizing littermate germ free wild type (WT) and NLRP6 deficient hosts with fecal microbial transplantation from SPF WT and Nlrp6-/- animals. Chimera studies were performed to assess the role of NLRP6 expression on host hematopoietic and non-hematopoietic cells. The allogeneic [B6Ly5.2→Nlrp6-/-] animals demonstrated significantly improved survival compared to the allogeneic [B6Ly5.2→B6] animals, demonstrating that the absence of NLRP6 in host non-hematopoietic cells is crucial for the protection against GVHD, but did not alter the therapeutic graft-versus-tumor effects after BMT. Our results unveil a novel role for NLRP6 and demonstrate a pathogenic role in GVHD that is independent of variations in its intestinal microbiome in contrast to its well-appreciated microbiome-dependent protective role in intestinal colitis and tumorigenesis.

2018-11-05 | ST001089 | MetabolomicsWorkbench

Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease

Project description:Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease

| PRJNA1065397 | ENA

Project description:Intestinal Microbiota Controls Graft-versus-Host Disease Independent of Donor-Host Genetic Disparity

| PRJNA979931 | ENA

mouse gut metagenome (410661)

Project description:Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity

| PRJNA980199 | ENA

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Project description:RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.

| 2005776 | ecrin-mdr-crc

The effect of LCN2 treatment on anti-inflammatory bone marrow derived macrophages

Project description:Allogeneic hematopoietic stem cell transplantation remains the most efficacious treatment for many hematological malignancies. However, its therapeutic potential is affected by the most prominent side effect graft versus host disease. Despite advances in the treatment of graft versus host disease in recent years, morbidity and mortality remains high, which requires the development of new treatment approaches. We therefore implemented mouse models to assess potential treatment options for graft versus host disease. In in vivo experiments, we had observed a protective effect of LCN2 on graft versus host disease of the gastrointestinal tract. We also observed higher numbers of anti-inflammatory macrophages in the intestinal tissues of these animals. Therefore, we aimed to determine potentially regulated genes in these cells by using an in vitro approach of LCN2-treated macrophages.

2024-01-24 | GSE226432 | GEO

Homo sapiens

Project description:Acute graft-versus-host disease (gene expression profiling)

| PRJNA100457 | ENA

gut metagenome

Project description:Metagenomic next-generation sequencing of Graft-versus-Host disease

| PRJNA396964 | ENA

Mus musculus

Project description:Donor T cells in ovarian graft versus host disease

| PRJNA321441 | ENA

mouse gut metagenome

Project description:Study of Intestinal microbiota in graft-versus-host disease